<table>
<thead>
<tr>
<th></th>
<th>Acknowledgements</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Welcome</td>
</tr>
<tr>
<td>3</td>
<td>Forum venue plan and list of exhibitors</td>
</tr>
<tr>
<td>4</td>
<td>Programme Overview</td>
</tr>
<tr>
<td>5</td>
<td>Scientific Programme</td>
</tr>
<tr>
<td>6</td>
<td>Posters</td>
</tr>
<tr>
<td>12</td>
<td>Scientific Information</td>
</tr>
<tr>
<td>16</td>
<td>General Information</td>
</tr>
<tr>
<td>17</td>
<td>Local Information</td>
</tr>
</tbody>
</table>
The Organizing Committee express their gratitude to the following Companies

ASAHI KASEI CORPORATION
ASTRAZENECA
ELI LILLY and COMPANY
H. LUNDBECK A/S
MERCK SHARP & DOHME

for their contribution as Sponsors of Symposia

ELI LILLY and COMPANY
H. LUNDBECK A/S
MERCK SHARP & DOHME
PHARMACIA & UPJOHN

for their valuable co-operation

MARTIN DUNITZ
SANOFI-SYNTHELABO
WISEPRESS LTD

for their participation in the pharmaceutical and publication exhibition
It is our pleasure to welcome you in Monte-Carlo to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).

Previous IFMAD meetings were very successful in providing a forum for the exchange of ideas on the latest treatment developments in the field of psychiatry. In these meetings a group of international experts met in Monte-Carlo and had the opportunity to address in an informal atmosphere some of the important topics in the field of mood and anxiety disorders and to discuss the recent data presented in a constructive and productive environment. The meetings were particularly appreciated for the high quality of the scientific contributions and the focused discussion from the attendees.

It is clear that the IFMAD annual meetings fulfil a need and provide a very efficient and agreeable formula for keeping up to date with current treatment issues. We can now build on past experience to make this year’s meeting an even more positive event in the scientific calendar and hope to renew old acquaintances as well as welcome an even wider audience.

We are pleased to invite you to join us for this useful and interesting opportunity to update your knowledge and have a glimpse into the future.

Siegfried Kasper  
Chairman

Stuart Montgomery  
Co-Chairman
Legenda Stands:
Wisepress  
n° 1-2
Sanofi-Synthelabo  
n° 3-4
Martin Dunitz  
n° 5
Wednesday, November 27, 2002

17.00-18.00 Opening of the Congress
Presentation of the 3rd International Forum Award for Mood and Anxiety Disorders donated by Merck Sharp & Dohme

S01 PLENARY LECTURE
Genetic predictors of response to antidepressants
A.F. Schatzberg (USA)

18.00-20.00 S02 DIFFICULT TO TREAT DEPRESSIONS:
EXPLORING NEW BREAKTHROUGHS
Chair: A.F. Schatzberg (USA)

S0201 Understanding the complexities of difficult-to-treat depressions: defining the burden of illness
A.F. Schatzberg (USA)

S0202 “Treatment resistant” depression: breaking new ground
S.H. Kennedy (Canada)

S0203 Bipolar depression: novel treatment solutions
M. Tohen (USA)

Sponsored by an unrestricted educational grant of ELI LILLY AND COMPANY

20.00-21.00 Opening reception - Welcome cocktail
### Thursday, November 28, 2002

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30-10.30</td>
<td><strong>S03 NEW DEVELOPMENTS IN DEPRESSION</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: <em>A.C. Altamura (Italy), R.A. Emsley (South Africa)</em></td>
</tr>
<tr>
<td>S0301</td>
<td>Rapid response antidepressants: is there any? <em>A.C. Altamura (Italy)</em></td>
</tr>
<tr>
<td>S0302</td>
<td>Update on agomelatine <em>R.A. Emsley (South Africa)</em></td>
</tr>
<tr>
<td>S0303</td>
<td>Update on escitalopram <em>H. Eriksson (Denmark)</em></td>
</tr>
<tr>
<td>S0304</td>
<td>Update on duloxetine <em>K. Demyttenaere (Belgium)</em></td>
</tr>
<tr>
<td>10.30-10.45</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>10.45-12.45</td>
<td><strong>S04 EVERYDAY CLINICAL USE AND POSSIBLE NEW INDICATIONS FOR A DUAL ACTION ANTIDEPRESSANT</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: <em>D. Baldwin (United Kingdom), M. Briley (France)</em></td>
</tr>
<tr>
<td>S0401</td>
<td>Essential considerations when choosing a modern antidepressant <em>D. Baldwin (United Kingdom)</em></td>
</tr>
<tr>
<td>S0402</td>
<td>Five years real-life experience of prescribing milnacipran <em>D. Papeta (France), an on-stage interview with M. Briley (France)</em></td>
</tr>
<tr>
<td>S0403</td>
<td>Japanese approaches to prescribing milnacipran (a round table chaired by D. Baldwin)</td>
</tr>
<tr>
<td></td>
<td>- Experience as a psychiatrist of milnacipran as first-line therapy <em>K. Yoshida (Japan)</em></td>
</tr>
<tr>
<td></td>
<td>- Experience in pain patients, especially glossalgia <em>A. Toyoafuku (Japan)</em></td>
</tr>
<tr>
<td></td>
<td>- Experience in depression with Parkinson’s disease <em>T. Maruyama (Japan)</em></td>
</tr>
<tr>
<td>S0404</td>
<td>Evidence-based prescribing or prescribing-based evidence? <em>S.A. Montgomery (United Kingdom)</em></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsored by an unrestricted educational grant of ASAHI KASEI CORPORATION</strong></td>
</tr>
<tr>
<td>12.45-13.30</td>
<td><strong>LUNCH AND POSTER DISPLAY</strong></td>
</tr>
</tbody>
</table>
Thursday, November 28, 2002

13.30-15.30 S05 BREAKTHROUGHS IN ANXIETY AND DEPRESSION
   Chair: J. Zohar (Israel), J. Loftus (Monte-Carlo)
   S0501 Are there inhibitor features which slow SSRI response?
         C. Sanchez (Denmark)
   S0502 Advances in the treatment of PMDD
         E. Eriksson (Sweden)
   S0503 Ten myths on PTSD
         J. Zohar (Israel)
   S0504 New treatments of attention deficit hyperactivity disorder
         J.K. Buitelaar (The Netherlands)

15.30-15.45 Coffee break

15.45-17.45 S06 CLINICAL EFFECTIVENESS IN BIPOLAR DISORDER
   Chair: S. Kasper (Austria)
   S0601 Introduction
         S. Kasper (Austria)
   S0602 The role of atypicals in mania
         T. Suppes (USA)
   S0603 Treatment options in bipolar depression
         G. Cassano (Italy)
   S0604 How to stabilise mood?
         E. Vieta (Spain)
         Panel discussion
         Conclusions
         S. Kasper (Austria)

Sponsored by an unrestricted educational grant of ASTRAZENECA
Friday, November 29, 2002

8.30-10.30  **S07 ADVANCES IN GAD**  
Chair: D. Nutt (United Kingdom), P. Robert (France)  
S0701 Targets for developing new treatments in anxiety  
*D. Nutt (United Kingdom)*  
S0702 The burden of GAD and depression  
*G. Burrows (Australia)*  
S0703 Placebo controlled studies on pregabalin  
*N. Strub (France)*  
S0704 Relapse prevention in GAD  
*C. Allgulander (Sweden)*

10.30-10.45  **Coffee break**

10.45-12.45  **S08 NEW GENERATION SSRI VERSUS DUAL ACTION ANTIDEPRESSANTS**  
Chair: S. Kasper (Austria)  
S0801 Pharmacological correlations to the clinical profiles  
*C. Sanchez (Denmark)*  
S0802 Is dual action necessary for effective treatment of depression?  
*S.A. Montgomery (United Kingdom)*  
S0803 Optimising pharmacotherapy in depressed patients  
*B. Hochstrasser (Switzerland)*  
S0804 New aspects in treatment of anxiety disorders  
*B. Bandelow (Germany)*

*Sponsored by an unrestricted educational grant of H. LUNDBECK A/S*

12.45-13.30  **LUNCH AND POSTER DISPLAY**
Friday, November 29, 2002

13.30-15.30  S09 THE OUTING OF SOCIAL ANXIETY DISORDER
Chair: J.P. Lepine (France), D. Baldwin (United Kingdom)

S0901 The biology of anxiety disorders
J. Tauscher (Austria)

S0902 Neurobiology of social phobia
D.J. Stein (South Africa)

S0903 Epidemiology and burden of social phobia
J.P. Lépine (France)

S0904 Recent advances in the treatment of social anxiety disorders
D. Baldwin (United Kingdom)

15.30-15.45  Coffee break

15.45-17.45  S10 THE CHANGING PARADIGM IN DEPRESSION AND THE ROLE
OF SUBSTANCE P (NK1 Receptor) ANTAGONISTS (spas)
Chair: H.J. Möller (Germany)

S1001 Molecular targeting of substance P related genes in depression
J. Mendlewicz (Belgium)

S1002 Neuroimaging and NK1 receptors in depression
R. Hargreaves (USA)

S1003 Determining the antidepressant mechanism of action of substance P antagonists
(spas)
G. Burrows (Australia)

S1004 Clinical significance of substance P antagonists (spas)
S. Kasper (Austria)

Sponsored by an unrestricted educational grant of MERCK SHARP & DOHME
S11 THE RISE OF BIPOLAR DEPRESSION
Chair: T. Suppes (USA), P. Baumann (Switzerland)

S1101 Lamotrigine in the treatment of bipolar depression
G. Evoniuk (USA)

S1102 How important are switch rates in bipolar depression
H. Grunze (Germany)

S1103 Maintenances therapy in bipolar depression
T. Suppes (USA)

S1104 Pluses and minuses of augmentation strategies
E. Vieta (Spain)

Coffee break

S12 NEW TREATMENT APPROACHES
Chair: H.J. Möller (Germany), S.A. Montgomery (United Kingdom)

S1201 Advances in somatization disorders
H.J. Möller (Germany)

S1202 Hypericum in affective disorders
Y. Lecrubier (France)

S1203 Advances with nemifitide in depression
S.A. Montgomery (United Kingdom)

S1204 Do discontinuation symptoms lead to relapse?
I. Hindmarch (United Kingdom)

CLOSURE
P01. High frequency repetitive transcranial magnetic stimulation (rTMS) in treatment refractory depression
G. Abraham, J.S. Lawson, M. David, R Milev (Kingston, Canada)

P02. The presenting symptoms of post traumatic stress disorder among children in Al-Amiria shelter
M.R. Al-Aboodi (Baghdad, Iraq)

P03. Difference in characteristic of soldiers with combat stress reaction applying to frontline versus home front treatment
D. Amital, J. Zohar (Israel)

P04. CYP2C19 dependent pharmacogenetics of (S)- and (R)-citalopram
P. Baumann, R.Nil, A. Souche, M. Brawand-Amey, M. Jonzier-Perey (Prilly- Lausanne, Switzerland)

P05. Escitalopram is well tolerated & more efficacious than citalopram in long-term treatment of moderately depressed patients
L. Colonna, E.H. Reines, H.F. Anderson (Rouen, France)

P06. Role of the BDNF in the ventral tegmental area in the development of dopaminergic behavioural supersensitivity induced by chronic imipramine
P.S. D’Aquila, F. Panin, P. Serra, A. Sini, A. Fresnu, M. Collu, G. Serra (Sassari, Italy)

P07. Duloxetine is effective in reducing anxiety symptoms associated with depression
M.J. Detke*, D.L. Dunner**, C.H. Mallinckrodt*, Y. Lu**, D.G. Perahia*** (*Indianapolis, IN, USA - ** Seattle, WA, USA, *** Windlesham, UK)

P08. Duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, exhibits excellent cardiovascular safety
M.J. Detke*, M.E. Thase**, C. Wiltse*, B.A. Pangallo*, E. Perrin*** (*Indianapolis, IN, USA - ** Pittsburgh, PA, USA, *** St. Cloud, France)

P09. Evaluation of duloxetine in the treatment of depression
M.J. Detke*, Y. Lu*, P. Tran*, C.H. Mallinckrodt*, C. Wiltse*, D.G. Perahia** (*Indianapolis, IN, USA - ** Windlesham, UK)

P10. Alleviation on painful physical symptoms associated with depression - association with higher remission rates?

P11. Safety and tolerability of the antidepressants duloxetine
M.J. Detke*, P. Tran*, C. Mallinckrodt*, E. Perrin** (*Indianapolis, IN, USA - ** St. Cloud, France)

P12. Patients with borderline personality disorder with and without affective disorder
S. Egli, L. Valach, M. Neueneschwander, H.J. Haug (Zurich, Switzerland)

P13. Levetiracetam in the treatment of acute mania
Forsthoff**, J. Langosch*, G. Scraub***, J. Walden*, H. Grunze** (*Freiburg, ** Munich, ***Zwickau, Germany)
P14. Effects of training on non-selected personnel regarding subjective coping strategies

P15. Luteal phase treatment of fluoxetine in premenstrual dysphoric disorder (PMDD): effect on sexual functioning
   S. Kornstein, C. Miner, E. Brown, J. Dillon (Richmond, VA, USA)

P16. Enhancing mental health awareness in children (6-12 years)
   B. Lauria-Horner, S.P. Kutcher, S.J. Brooks (Halifax, Canada)

P17. GAD in the elderly - Is there evidence of safe and effective drug treatments?
   M.G. Livingston, H.M. Livingston (Glasgow, UK)

P18. Involvement of dopamine D4 receptors in naloxone-induced morphine withdrawal syndromes with morphine in mice
   T. Mamiya, T. Matsumura, M. Ukai (Nagoya, Japan)

P19. Depression - Multidimensional psychotherapy approach
   A. Martisching, N. Habsa, B. Steinbrenner, M. Schonauer-Cejpek, M. Steinbauer (Graz, Austria)

P20. Milnacipran is effective in treating depression associated with Parkinson’s disease
   T. Maruyama (Iida City, Japan)

P21. Six month compliance with fluoxetine or paroxetine treatment in depressed outpatients
   D. Steemans, E. Verhaeghen (Leuven, Belgium)

P22. Escitalopram is at least as effective as venlafaxine XR in the treatment of depression and better tolerated
   S.A. Montgomery, A.K. Huusom, J. Bothmer (London, UK)

P23. The clinical use of Milnacipran for depression
   S. Morishita*, S. Arita** (*Kurashiki, **Hirakata, Japan)

P24. Effects of milnacipran on anxiety and depression caused by workplace stress
   K. Nakayama (Tokyo, Japan)

P25. Sleeping complaints in panic disorder patients
   T. Overbeek, F. Kruizinga, T. Baars, R. van Diest, K. Schruers, E. Griez (Maastricht, The Netherlands)

P26. Symptom-profile of depression in OCD and panic disorder
   T. Overbeek, M. Kersemaekers, K. Schruers, E. Griez (Maastricht, The Netherlands)

P27. Duloxetine in the long-term treatment of major depressive disorders
   J. Raskin*, D.J. Goldstein**, C. Mallinckrodt**, M.B. Ferguson**, E. Perrin*** (*Scarborough, ON, Canada, **Indianapolis, IN, USA, ***St. Cloud, France)

P28. Escitalopram is efficacious and well tolerated in depressed patients in primary care
   E.H. Reines, H. Loft, U. Lepola (Copenhagen, Denmark)
P29. Switching depressed patients from citalopram to escitalopram treatment is safe and effective
E.H. Reines, L.E. Glesner, N. Despiegel (Copenhagen, Denmark)

P30. In vitro and in vivo effects of citalopram and its enantiomers on the serotonin uptake transporter

P31. Escitalopram potently reverses conditioned footshock-induced suppression of exploratory activity in rats - an animal model of generalised anxiety
C. Sanchez*, M. Papp** (*Valby-Copenhagen, Denmark, **Krakow, Poland)

P32. Temperament and character determinants of a specific phobia
S. Settineri, F. Tati’, L. Di Blasi, L. Gambacurta, L. Riggio (Messina, Italy)

P33. Character of course of seasonal affective disorders
G. Simutkin (Tomsk, Russia)

P34. Remifentanil vs methohexital for electroconvulsive therapy
P. Sullivan, E. Sinz, G. Hoobs, E. Glover, J. Cain, A. Kofke (Morgantown, WV, USA)

P35. Comparison of milnacipran and fluvoxamine in the clinical treatment of major depression
A. Sumiyoshi (Sagamihara, Japan)

P36. Anxiety disorders during pregnancy and postnatal depression at 6 weeks postpartum
A.L. Sutter, V. Giaconne-Marcesco, E. Glatigny, H. Verdoux (Bordeaux, France)

P37. Efficacy of milnacipran in patients with chronic orthopaedic pain including degenerative spondylosis and osteoarthritis
H. Tanikawa (Nagano, Japan)

P38. Mood altering Medication Prescriptions among severely mentally ill: results from a survey
R. Tempier, B. McGrath (Montreal, Canada)

P39. Efficacy of milnacipran for glossodynia patients
A. Toyofuku (Fukuoka, Japan)

P40. Usefulness of milnacipran in the treatment of generalized anxiety disorder
T. Tsukamoto, R. Kindo, K. Ichikawa (Yokokawa, Japan)

P41. Escitalopram provides continued improvement during long-term treatment of depressed patients in primary care
A. Wade, N. Despiegel, E. Reines (Glasgow, UK)

P42. Persistence with initially prescribed antipsychotic medication and economic outcomes in the treatment of bipolar disorder
R.E. White (Wilmington, DE, USA)

P43. Clinical efficacy of SNRI, Milnacipran, on a depressive state in a department of neurology
K. Yamane, A. Shirata, T. Takeda, M. Kobayashi (Koriyama, Japan)
P44. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients: the second report

P45. Venlafaxine utilization in mood disorders with resistant depressive symptoms
   G. Tavormina (Provaglio d’Iseo, Italy)

P46. The psychological impact of Al-Ameryah bombardment on the neighbourhood children
   M. Sulaiman Younis (Baghdad, Irak)

P47. The melancholia: transnosographic aspects
   P. Franco, C. Taranto, A. Urbani, S. De Risio (Sassari, Italy)
European Accreditation

The European Accreditation Committee for Continuing Medical Education in CNS has granted accreditation to the scientific program of the 3rd International Forum on Mood and Anxiety Disorders (Monte-Carlo, November 27-30, 2002)

23 CME credits have been granted for this activity. Those interested in obtaining these credits are required to fill in a special feedback rating form available in the congress bags or at the Secretariat Desk.

Each medical specialist should claim only those hours of activity that he/she actually spends on the educational activity.

Audio-Visual Facilities

Slide projectors or equipment for computerised Power Point presentations will be provided during the scientific sessions. All slides must be mounted in glass with plastic frames. Please use only 24 x 36 mm Leica slides.

Slides and floppy disks for Power Point presentations can be tested prior to presentation in the slide preview room. Slides and floppy disks or Cd-Rom must be handed over to the Slide Preview Room at least forty minutes before the beginning of the sessions and must be collected directly by the Speakers at the end of the session.

*It is essential for the smooth running of the sessions that all Speakers hand in their slides and Power Point presentations in due time.*

Certificate of Attendance

A certificate of attendance will be provided on request at the registration desk on the last day of the Congress.

Pharmaceutical and Publication Exhibition

A pharmaceutical and publication exhibition takes place in the Forum venue throughout the Scientific works.

Posters

All the accepted abstracts are scheduled for poster presentation. An area (Salle d’Or 2) has been prepared for poster exhibition with the following schedule:

- Thursday, November 28 and Friday, November 29 from 10.00 to 18.00
- Saturday, November 30 from 10.00 to 13.00

Set-up and removal time is as follows:
- Thursday, November 28 from 09.00 to 10.00
- Saturday, November 30 from 13.00 to 14.00

**Poster size: cm 150 height - cm 90 base**

Special attention to posters will be given during lunchtime. During that time, in fact, posters should be attended by the Authors for viewing and discussion.

Authors must be registered to the Congress.

Language

The official language of the Congress is English. No simultaneous translation will be provided.
**Congress Venue**

MONTE-CARLO GRAND HOTEL  
12, Av. des Spélugues  
MC 98000 Monaco  
Ph +377 93506500  
Fax +377 93300157

**Congress Secretariat**

All Congress material and documentation are available from the Forum registration desk located in the foyer of the Monte-Carlo Grand Hotel.

**Opening hours**

- Wednesday, November 27, 2002: 14.00/20.00
- Thursday, November 28, 2002: 08.00/18.30
- Friday, November 29, 2002: 08.00/18.30
- Saturday, November 30, 2002: 08.00/13.00

**Badges**

Participants are requested to wear their badge during all Forum activities and social events. The participants’ registration fee includes admission to all scientific sessions and exhibition, Forum material, welcome reception, coffee breaks and working lunches. Euro 30 will be charged for replacement of a lost badge.  
Congress badges are distinguished as follows:  
Participants: Transparent  
Speakers: Blue  
Exhibitors: Green  
Staff: Red

**Welcome Cocktail**

All delegates are cordially invited to attend the Welcome Cocktail of the congress, which is held on Wednesday, November 27, at 20.00 in the Foyer of the Monte-Carlo Grand Hotel.

**Coffee Breaks and Lunches**

During the Congress session breaks, coffee breaks and lunches are served free of charge to all registered participants wearing Congress badges.
Insurance

The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel. The insurance should be purchased in your country of origin.

Delegates are kindly requested to keep their mobile phones in off position in the Room where the scientific sessions are being held.

The “3rd International Forum on Mood and Anxiety Disorders” wishes to be a non-smoking congress. Participants are kindly requested to refrain from smoking in the congress venue, including exhibition area and restrooms.
**Hotels**

**MONTE-CARLO GRAND HOTEL****
12, Av. des Spélugues - Ph +377 93506500

**HOTEL METROPOLE****
4, Av. de la Madone - Ph +377 93151515

**HOTEL MIRABEAU****
1/3, Av. Princesse Grace - Ph +377 92166565

**USEFUL INFORMATION ABOUT MONACO**

Situated in the far South East corner of France, the Principality of Monaco stretches along a four kilometre strip of coast, along the Mediterranean Sea, at the foot of the Southern Alps.

Its particularly mild and temperate climate together with an exceptional amount of sunshine – more than 300 days per year – make it a very welcoming place. In November the average temperature is 12°C during the day.

**Currency**

The currency in Monaco is Euro. There are a number of bureaux de change which are open all day, including Sunday and bank holidays. Your hotel will provide you with details of your nearest bureau de change.

**Electricity**

The standard voltage in Monaco is 220 V.

**WHAT TO DO IN MONACO**

A range of leisure activities:

There is so much going on in Monaco that no two days are ever the same. In addition to the major events organised throughout the year, there is plenty of time for leisure activities which are particularly enjoyable in the Principality.

Outdoor sporting activities are enjoyed thanks to a very mild climate:

- tennis in the unique setting of the Monte-Carlo Country Club
- golf on the 18-hole course of the Monte-Carlo Golf Course
- jogging, on the “soft” surface track along the beaches.

The pleasure of shopping, to be done in the heart of the city, in elegant luxury shops, with prestigious names, or in the typical back streets of the Old Town, or in the shopping arcades of the Park Palace, the Metropole or Fontvieille Shopping Centres.
Finally, the numerous museums, places of interest and touristic activities:

- the Exotic Garden and the Observatory Cave, the largest collection of succulent rock plants in the world
- the Museum of Prehistoric Anthropology, with its collection of human and extinct animal remains from the archaeological excavations of the region
- the Oceanographic Museum, with its famous “Aquarium”, where the rarest species of fish are displayed in all shapes and colours
- the Old Town, where you can discover, in the narrow medieval alleyways, the picturesque Place Saint Nicolas and Placette Bosio, the Cathedral and the Museum of Old Monaco
- the Prince’s Palace and the Palace Square, that is the centre of attention every day at 11.55 precisely, for the Changing of the Guard
- the History of the Princes of Monaco (Wax Museum), where historic scenes of the Grimaldi Dynasty are illustrated

**Useful Telephone Numbers**

**Ambulance and Fire Services**
+377 93301945 or 18

**Police**
+377 93153015 or 17

**Monaco Hospital**
+377 97989769